2020Phase 3 human evidence
Evidence strength A · 90/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
- Directness
- 80/100
- Replication
- 65/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Effect of Abaloparatide vs Alendronate on Fracture Risk Reduction in Postmenopausal Women With Osteoporosis.
The ACTIVE study demonstrated the antifracture efficacy of abaloparatide in postmenopausal women with osteoporosis.
- Authors
- Benjamin Z Leder, Bruce Mitlak, Ming-Yi Hu, Gary Hattersley, Richard S Bockman
- Source
- The Journal of clinical endocrinology and metabolism
- DOI
- 10.1210/clinem/dgz162
- PubMed
- 31674644
Open original source2016Phase 3 human evidence
Evidence strength A · 90/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
- Directness
- 80/100
- Replication
- 65/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.
Additional therapies are needed for prevention of osteoporotic fractures.
- Authors
- Paul D Miller, Gary Hattersley, Bente Juel Riis, Gregory C Williams, Edith Lau, Luis Augusto Russo, Peter Alexandersen, Cristiano A F Zerbini, Ming-yi Hu, Alan G Harris, Lorraine A Fitzpatrick, Felicia Cosman
- Source
- JAMA
- DOI
- 10.1001/jama.2016.11136
- PubMed
- 27533157
Open original source2017Phase 3 human evidence
Evidence strength A · 90/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
- Directness
- 80/100
- Replication
- 65/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Effects of abaloparatide-SC (BA058) on bone histology and histomorphometry: The ACTIVE phase 3 trial.
There are a number of effective treatments for osteoporosis but most are in the antiresorptive class of compounds.
- Authors
- Carolina A Moreira, Lorraine A Fitzpatrick, Yamei Wang, Robert R Recker
- Source
- Bone
- DOI
- 10.1016/j.bone.2016.11.004
- PubMed
- 27826127
Open original source2023Phase 3 human evidence
Evidence strength A · 90/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
- Directness
- 80/100
- Replication
- 65/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
The effects of abaloparatide on hip geometry and biomechanical properties in Japanese osteoporotic patients assessed using DXA-based hip structural analysis: results of the Japanese phase 3 ACTIVE-J trial.
Daily subcutaneous injection of 80 μg abaloparatide increased bone mineral density in Japanese patients with osteoporosis at high fracture risk in the ACTIVE-J trial.
- Authors
- Teruki Sone, Kazuhiro Ohnaru, Takumi Sugai, Akiko Yamashita, Nobukazu Okimoto, Tetsuo Inoue, Toshio Matsumoto
- Source
- Archives of osteoporosis
- DOI
- 10.1007/s11657-023-01344-5
- PubMed
- 38030806
Open original source2025Phase 3 human evidence
Evidence strength A · 90/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
- Directness
- 80/100
- Replication
- 65/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Bone turnover markers predict changes in bone mineral density in men treated with abaloparatide: results from the abaloparatide for the treatment of men with osteoporosis (ATOM) study.
Early increases in bone turnover markers (BTMs) in response to anabolic therapy correlate with 18-mo BMD increases in postmenopausal women with osteoporosis; however, this relationship has not been assessed in men.
- Authors
- Richard Eastell, Jacques P Brown, Robert A Adler, E Michael Lewiecki, Neil Binkley, Eric S Orwoll, David Kendler, Bruce H Mitlak, Yamei Wang
- Source
- Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
- DOI
2024Phase 3 human evidence
Evidence strength A · 90/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
- Directness
- 80/100
- Replication
- 65/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Effects of Abaloparatide on Bone Mineral Density in Proximal Femoral Regions Corresponding to Arthroplasty Gruen Zones: A Study of Postmenopausal Women with Osteoporosis.
Low hip bone mineral density (BMD) in patients who undergo total hip arthroplasty (THA) increases the risk of periprosthetic fractures, implant instability, and other complications.
- Authors
- Neil P Sheth, James Russell Smith, Renaud Winzenrieth, Ludovic Humbert, Yamei Wang, John I Boxberger, Mathias P Bostrom
- Source
- The Journal of bone and joint surgery. American volume
- DOI
- 10.2106/jbjs.23.01334
- PubMed
- 38691582
2022Phase 1–2 human evidence
Evidence strength B · 80/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
- Directness
- 80/100
- Replication
- 65/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
The Efficacy and Safety of Abaloparatide-SC in Men With Osteoporosis: A Randomized Clinical Trial.
Abaloparatide significantly increased bone mineral density (BMD) in women with postmenopausal osteoporosis and decreased risk of vertebral, nonvertebral, and clinical fractures compared with placebo.
- Authors
- Edward Czerwinski, Jose Cardona, Rafal Plebanski, Chris Recknor, Tamara Vokes, Kenneth G Saag, Neil Binkley, E Michael Lewiecki, Jonathan Adachi, Dorota Knychas, David Kendler, Eric Orwoll
- Source
- Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
- DOI
- 10.1002/jbmr.4719
- PubMed
2018Phase 1–2 human evidence
Evidence strength B · 80/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
- Directness
- 80/100
- Replication
- 65/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis.
In women with postmenopausal osteoporosis, we investigated the effects of 24 months of treatment with alendronate (ALN) following 18 months of treatment with abaloparatide (ABL) or placebo (PBO).
- Authors
- Henry G Bone, Felicia Cosman, Paul D Miller, Gregory C Williams, Gary Hattersley, Ming-Yi Hu, Lorraine A Fitzpatrick, Bruce Mitlak, Socrates Papapoulos, René Rizzoli, Robin K Dore, John P Bilezikian
- Source
- The Journal of clinical endocrinology and metabolism
- DOI
- 10.1210/jc.2018-00163
- PubMed
2025Phase 1–2 human evidence
Evidence strength B · 80/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
- Directness
- 80/100
- Replication
- 65/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Probability of achieving bone mineral density treatment targets with abaloparatide and teriparatide.
The goal of treatment for women at high risk of fracture who have a T-score ≤-2.5 is to mitigate fracture risk by achieving T-scores at least above -2.5.
- Authors
- Felicia Cosman, Bruce H Mitlak, Yamei Wang, Leny Pearman, Carolina A Moreira, E Michael Lewiecki, Steven R Cummings
- Source
- Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
- DOI
- 10.1093/jbmr/zjaf053
- PubMed
- 40214193
Open original source2023Phase 1–2 human evidence
Evidence strength B · 80/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
- Directness
- 80/100
- Replication
- 65/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Abaloparatide dose-dependently increases bone mineral density in postmenopausal women with osteoporosis: a phase 2 study.
This study aimed to determine the efficacy of abaloparatide in increasing bone mineral density (BMD) and its safety in postmenopausal Japanese women with osteoporosis.
- Authors
- Toshio Matsumoto, Teruki Sone, Akiko Yamashita, Tetsuo Inoue
- Source
- Journal of bone and mineral metabolism
- DOI
- 10.1007/s00774-023-01455-6
- PubMed
- 37505256
Open original source2023Phase 1–2 human evidence
Evidence strength B · 80/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
- Directness
- 80/100
- Replication
- 65/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Efficacy and Safety of Transdermal Abaloparatide in Postmenopausal Women with Osteoporosis: A Randomized Study.
Anabolic therapies, recommended for patients at very high fracture risk, are administered subcutaneously (SC).
- Authors
- E Michael Lewiecki, Edward Czerwinski, Chris Recknor, Anna Strzelecka, Guillermo Valenzuela, Mary Lawrence, Stuart Silverman, Jose Cardona, Susan M Nattrass, Neil Binkley, Miriam Annett, Leny Pearman
- Source
- Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
- DOI
- 10.1002/jbmr.4877
- PubMed
- 37417725
2017Observational human evidence
Evidence strength B · 70/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
- Directness
- 80/100
- Replication
- 65/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Profile of Abaloparatide and Its Potential in the Treatment of Postmenopausal Osteoporosis.
Abaloparatide (previously known as BA058) is a synthetic 34-amino acid peptide and novel selective activator of parathyroid hormone receptor 1 (PTHR1) currently under development as a new anabolic agent in the management of osteoporosis.
- Authors
- Sri Harsha Tella, Anuhya Kommalapati, Ricardo Correa
- Source
- Cureus
- DOI
- 10.7759/cureus.1300
- PubMed
- 28680788
Open original source2017Observational human evidence
Evidence strength C · 65/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
- Directness
- 80/100
- Replication
- 65/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Abaloparatide: First Global Approval.
Abaloparatide (Tymlos™) is a synthetic peptide analogue of human parathyroid hormone-related protein that was developed by Radius Health as an osteoanabolic agent for the treatment of postmenopausal osteoporosis.
- Authors
- Matt Shirley
- Source
- Drugs
- DOI
- 10.1007/s40265-017-0780-7
- PubMed
- 28624872
Open original source2023Observational human evidence
Evidence strength A · 88/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
- Directness
- 65/100
- Replication
- 65/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Evidence for the cardiovascular effects of osteoporosis treatments in randomized trials of post-menopausal women: A systematic review and Bayesian network meta-analysis.
Osteoporosis medications have been reported to have beneficial and harmful cardiovascular effects.
- Authors
- Alexander H Seeto, Mina Tadrous, Abadi K Gebre, Joshua R Lewis, Howard A Fink, Peter R Ebeling, Alexander J Rodríguez
- Source
- Bone
- DOI
- 10.1016/j.bone.2022.116610
- PubMed
- 36372197
Open original source2023Observational human evidence
Fracture risk reduction and safety by osteoporosis treatment compared with placebo or active comparator in postmenopausal women: systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials.
To review the comparative effectiveness of osteoporosis treatments, including the bone anabolic agents, abaloparatide and romosozumab, on reducing the risk of fractures in postmenopausal women, and to characterise the effect of antiosteoporosis drug treatments on the risk of fractures according to baseline risk factors.
- Authors
- Mina Nicole Händel, Isabel Cardoso, Cecilie von Bülow, Jeanett Friis Rohde, Anja Ussing, Sabrina Mai Nielsen, Robin Christensen, Jean-Jacques Body, Maria Luisa Brandi, Adolfo Diez-Perez, Peyman Hadji, Muhammad Kassim Javaid
- Source
- BMJ (Clinical research ed.)
- DOI
- 10.1136/bmj-2021-068033
- PubMed
- 37130601
Open original source2025Observational human evidence
Evidence strength B · 76/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
- Directness
- 80/100
- Replication
- 65/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Comparative Effectiveness of Abaloparatide and Teriparatide in Women 50 Years of Age and Older: Update of a Real-World Retrospective Analysis.
Abaloparatide and teriparatide are osteoanabolic treatments indicated for postmenopausal women and men with osteoporosis at high risk of fracture.
- Authors
- Laila Tabatabai, Felicia Cosman, Jeffrey R Curtis, Kristi T DeSapri, Clayton T LaBaume, Jean-Yves Reginster, René Rizzoli, Bernard Cortet, Yamei Wang, Joseph Chiodo, Bruce H Mitlak
- Source
- Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
- DOI
- 10.1016/j.eprac.2024.10.017
2024Observational human evidence
Evidence strength A · 88/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
- Directness
- 80/100
- Replication
- 65/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
The Safety and Efficacy of Abaloparatide on Postmenopausal Osteoporosis: A Systematic Review and Meta-analysis.
The aging of the population increases the incidence of postmenopausal osteoporosis, which threatens the health of elderly women.
- Authors
- Fuxin Xu, Yurun Wang, Xinjian Zhu
- Source
- Clinical therapeutics
- DOI
- 10.1016/j.clinthera.2023.12.010
- PubMed
- 38307725
Open original source2025Observational human evidence
Evidence strength A · 88/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
- Directness
- 65/100
- Replication
- 65/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
PTH1 receptor agonists for fracture risk: a systematic review and network meta-analysis.
Osteoporosis, defined by reduced bone mineral density and macro- and micro-architectural degradation, leads to increased fracture risk, particularly in aging populations.
- Authors
- Charlotte Beaudart, Nicola Veronese, Jonathan Douxfils, Jotheeswaran Amuthavalli Thiyagarajan, Francesco Bolzetta, Paolo Albanese, Gianpaolo Voltan, Majed Alokail, Nicholas C Harvey, Nicholas R Fuggle, Olivier Bruyère, René Rizzoli
- Source
- Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA
- DOI
2019Observational human evidence
Evidence strength A · 88/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
- Directness
- 65/100
- Replication
- 65/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Efficacy of Pharmacological Therapies for the Prevention of Fractures in Postmenopausal Women: A Network Meta-Analysis.
Osteoporosis and osteopenia are associated with increased fracture incidence in postmenopausal women.
- Authors
- Patricia Barrionuevo, Ekta Kapoor, Noor Asi, Fares Alahdab, Khaled Mohammed, Khalid Benkhadra, Jehad Almasri, Wigdan Farah, Maria Sarigianni, Kalpana Muthusamy, Alaa Al Nofal, Qusay Haydour
- Source
- The Journal of clinical endocrinology and metabolism
- DOI
- 10.1210/jc.2019-00192
- PubMed
- 30907957
Open original source2023Observational human evidence
Effectiveness and Safety of Treatments to Prevent Fractures in People With Low Bone Mass or Primary Osteoporosis: A Living Systematic Review and Network Meta-analysis for the American College of Physicians.
The prevalence of osteoporosis is increasing in the United States.
- Authors
- Chelsea Ayers, Devan Kansagara, Brittany Lazur, Rongwei Fu, Amy Kwon, Curtis Harrod
- Source
- Annals of internal medicine
- DOI
- 10.7326/m22-0684
- PubMed
- 36592455
Open original source2021Observational human evidence
Evidence strength B · 70/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
- Directness
- 80/100
- Replication
- 65/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Abaloparatide: A review of preclinical and clinical studies.
Osteoporosis is a debilitating disease characterized by reduced bone mineral density and an increased risk of fractures.
- Authors
- Mikkel Bo Brent
- Source
- European journal of pharmacology
- DOI
- 10.1016/j.ejphar.2021.174409
- PubMed
- 34364879
Open original source2019Observational human evidence
Evidence strength C · 70/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
- Directness
- 80/100
- Replication
- 65/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Abaloparatide, the second generation osteoanabolic drug: Molecular mechanisms underlying its advantages over the first-in-class teriparatide.
Abaloparatide is an analog of human parathyroid hormone-related protein (PTHrP) that has recently been approved for the treatment of post-menopausal osteoporosis.
- Authors
- Sharmistha Bhattacharyya, Subhashis Pal, Naibedya Chattopadhyay
- Source
- Biochemical pharmacology
- DOI
- 10.1016/j.bcp.2019.05.024
- PubMed
- 31136739
Open original source2019Observational human evidence
Evidence strength C · 70/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
- Directness
- 80/100
- Replication
- 65/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Abaloparatide: A new pharmacological option for osteoporosis.
The efficacy and safety of abaloparatide, a parathyroid hormone-related protein analog for the treatment of osteoporosis in postmenopausal women at high fracture risk, is reviewed.
- Authors
- Allyson Sleeman, Jennifer N Clements
- Source
- American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
- DOI
- 10.1093/ajhp/zxy022
- PubMed
- 30689744
Open original source2018Observational human evidence
Evidence strength C · 70/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
- Directness
- 80/100
- Replication
- 65/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Abaloparatide: Review of a Next-Generation Parathyroid Hormone Agonist.
To review the efficacy, safety, and economics of abaloparatide in the treatment of postmenopausal osteoporosis.
- Authors
- Eric G Boyce, Yvonne Mai, Christopher Pham
- Source
- The Annals of pharmacotherapy
- DOI
- 10.1177/1060028017748649
- PubMed
- 29241341
Open original source2019Laboratory research
Evidence strength C · 62/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
- Directness
- 80/100
- Replication
- 65/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Precisely Controlled Delivery of Abaloparatide through Injectable Hydrogel to Promote Bone Regeneration.
Side-effects from allograft, limited bone stock, and site morbidity from autograft are the major challenges to traditional bone defect treatments.
- Authors
- Ziyu Ning, Baoyu Tan, Bo Chen, Dzi Shing Aaron Lau, Tak Man Wong, Tianhao Sun, Songlin Peng, Zhaoyang Li, William Weijia Lu
- Source
- Macromolecular bioscience
- DOI
- 10.1002/mabi.201900020
- PubMed
- 31066995
Open original source